

Mainstay Medical Appoints Wolfgang Frisch as VP and Managing Director for Germany

Dublin – Ireland, 20 June 2018 – Mainstay Medical International plc (“**Mainstay**” or the “**Company**”, Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, announces that it has appointed industry veteran Wolfgang Frisch as Vice President and Managing Director for Germany, effective 2 July.

Mainstay Medical has launched ReActiv8 in Germany, its first commercial market. Commercialization began in earnest over the last few months, following the Company’s fundraising that was completed in February 2018. Mr. Frisch will be instrumental in driving the commercial strategy forward, with a focus on adoption in a select number of high volume spine care centers to develop reference sites.

Mr. Frisch has over 30 years’ experience in the medical technology industry, including 20 years in leadership positions in sales, market access, market development, and general management positions, having spent a combined 15 years with Stryker and Medtronic. He most recently served on the executive board of Medtronic Germany, where he was also managing director for the strategic and tactical deployment of the sales organization in the entirety of Germany.

Jason Hannon, CEO of Mainstay, said: *“I am delighted to announce that Wolfgang will be joining us as Managing Director for Germany. It is reflective of the clinical and market opportunity of ReActiv8 that we are able to attract a leader of Wolfgang’s caliber. Wolfgang will be instrumental in growing our commercial business in Germany, building clinical data around the commercial experience, and developing key reference sites throughout Germany who reflect their experience with ReActiv8 to the rest of the world.”*

- End -

About Mainstay

Mainstay is a medical device company focused on bringing to market an innovative implantable restorative neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands, and is listed on the regulated market of Euronext Paris (MSTY.PA) and the ESM of Euronext Dublin (MSTY.IE).

About Chronic Low Back Pain

One of the recognized root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilize the spine in the low back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.

People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilization put a significant burden on individuals, families, communities, industry and governments.

Further information can be found at www.mainstaymedical.com

CAUTION – in the United States, ReActiv8 is limited by federal law to investigational use only.

PR and IR Enquiries:

Consilium Strategic Communications (international strategic communications - business and trade media)

Chris Gardner, Jessica Hodgson, Nicholas Brown

Tel: +44 203 709 5700 / +44 7921 697 654

Email: mainstaymedical@consilium-comms.com

FTI Consulting (for Ireland):

Jonathan Neilan

Tel: +353 1 765 0886

Email: jonathan.neilan@fticonsulting.com

NewCap (for France)

Julie Coulot

Tel: +33 1 44 71 20 40

Email: jcoulot@newcap.fr

AndreasBohne.Com/Kötting Consulting (for Germany)

Andreas Bohne

Tel : +49 2102 1485368

Email : abo@andreasbohne.com

Wilhelm Kötting

Tel: +49 69 75913293

Email: wkotting@gmail.com

Investor Relations:

LifeSci Advisors, LLC

Brian Ritchie

Tel: + 1 (212) 915-2578

Email: britchie@lifesciadvisors.com

ESM Advisers:

Davy

Fergal Meegan or Barry Murphy

Tel: +353 1 679 6363

Email: fergal.meegan@davy.ie or barry.murphy2@davy.ie

Forward looking statements

This announcement includes statements that are, or may be deemed to be, forward looking statements. These forward looking statements can be identified by the use of forward looking terminology, including the terms “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “should”, “will”, or “explore” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward looking statements include all matters that are not historical facts. They appear throughout this announcement and include, but are not limited to, statements regarding the Company’s intentions, beliefs or current expectations concerning, among other things, the Company’s results of operations, financial position, prospects, financing strategies, expectations for product design and development, regulatory applications and approvals, reimbursement arrangements, costs of sales and market penetration.

By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances. Forward looking statements are not guarantees of future performance and the actual results of the Company’s operations, and the development of its main product, the markets and the industry in which the Company operates, may differ materially from those described in, or suggested by, the forward looking statements contained in this announcement. In addition, even if the Company’s results of operations, financial position and growth, and the development of its main product and the markets and the industry in which the Company operates, are consistent with the forward looking statements contained in this announcement, those results or developments may not be indicative of results or developments in subsequent periods. A number of factors could cause results and developments of the Company to differ materially from those expressed or implied by the forward

looking statements including, without limitation, the successful launch and commercialization of ReActiv8, the progress and success of the ReActiv8-B Clinical Trial, general economic and business conditions, the global medical device market conditions, industry trends, competition, changes in law or regulation, changes in taxation regimes, the availability and cost of capital, the time required to commence and complete clinical trials, the time and process required to obtain regulatory approvals, currency fluctuations, changes in its business strategy, political and economic uncertainty. The forward-looking statements herein speak only at the date of this announcement.